COUMADIN- warfarin sodium tablet
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use COUMADIN safely and effectively. See full prescribing information for COUMADIN.<br><br>COUMADIN (warfarin sodium) tablets, for oral use<br>COUMADIN (warfarin sodium) for injection, for intravenous use<br>Initial U.S. Approval: 1954
These highlights do not include all the information needed to use COUMADIN safely and effectively. See full prescribing information for COUMADIN.<br><br>COUMADIN (warfarin sodium) tablets, for oral use<br>COUMADIN (warfarin sodium) for injection, for intravenous use<br>Initial U.S. Approval: 1954 These highlights do not include all the information needed to use COUMADIN safely and effectively. See full prescribing information for COUMADIN.<br><br>COUMADIN (warfarin sodium) tablets, for oral use<br>COUMADIN (warfarin sodium) for injection, for intravenous use<br>Initial U.S. Approval: 1954 These highlights do not include all the information needed to use COUMADIN safely and effectively. See full prescribing information for COUMADIN.<br><br>COUMADIN (warfarin sodium) tablets, for oral use<br>COUMADIN (warfarin sodium) for injection, for intravenous use<br>Initial U.S. Approval: 1954 WARNING: BLEEDING RISKSee full prescribing information for complete boxed warning.
RECENT MAJOR CHANGESINDICATIONS AND USAGECOUMADIN is a vitamin K antagonist indicated for:
Limitation of Use COUMADIN has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. (1) DOSAGE FORMS AND STRENGTHSCONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSMost common adverse reactions to COUMADIN are fatal and nonfatal hemorrhage from any tissue or organ. (6)
DRUG INTERACTIONS
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 3/2018 |
COUMADIN® is indicated for:
Limitations of Use
COUMADIN has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.
COUMADIN tablets are single scored with one face imprinted numerically with 1, 2, 2-1/2, 3, 4, 5, 6, 7-1/2, or 10 superimposed and inscribed with “COUMADIN” and with the opposite face plain.
COUMADIN tablets are supplied in the following strengths:
COUMADIN Tablets | |
Strength | Color |
1 mg | pink |
2 mg | lavender |
2-1/2 mg | green |
3 mg | tan |
4 mg | blue |
5 mg | peach |
6 mg | teal |
7-1/2 mg | yellow |
10 mg | white (dye-free) |
COUMADIN for injection is available in a vial containing 5 mg of lyophilized powder.
COUMADIN is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.5) and Use in Specific Populations (8.1)]. COUMADIN can cause fetal harm when administered to a pregnant woman. COUMADIN exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If COUMADIN is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Warnings and Precautions (5.6) and Use in Specific Populations (8.1)].
COUMADIN can cause major or fatal bleeding. Bleeding is more likely to occur within the first month. Risk factors for bleeding include high intensity of anticoagulation (INR >4.0), age greater than or equal to 65, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic factors [see Clinical Pharmacology (12.5)], certain concomitant drugs [see Drug Interactions (7)], and long duration of warfarin therapy.
Perform regular monitoring of INR in all treated patients. Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shortest duration of therapy appropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding.
Drugs, dietary changes, and other factors affect INR levels achieved with COUMADIN therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs [see Drug Interactions (7)].
Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [see Patient Counseling Information (17)].
Necrosis and/or gangrene of skin and other tissues is an uncommon but serious risk (<0.1%). Necrosis may be associated with local thrombosis and usually appears within a few days of the start of COUMADIN therapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported.
Careful clinical evaluation is required to determine whether necrosis is caused by an underlying disease. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. Discontinue COUMADIN therapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary.
Anticoagulation therapy with COUMADIN may enhance the release of atheromatous plaque emboli. Systemic atheroemboli and cholesterol microemboli can present with a variety of signs and symptoms depending on the site of embolization. The most commonly involved visceral organs are the kidneys followed by the pancreas, spleen, and liver. Some cases have progressed to necrosis or death. A distinct syndrome resulting from microemboli to the feet is known as “purple toes syndrome.” Discontinue COUMADIN therapy if such phenomena are observed. Consider alternative drugs if continued anticoagulation therapy is necessary.
Do not use COUMADIN as initial therapy in patients with heparin-induced thrombocytopenia (HIT) and with heparin-induced thrombocytopenia with thrombosis syndrome (HITTS). Cases of limb ischemia, necrosis, and gangrene have occurred in patients with HIT and HITTS when heparin treatment was discontinued and warfarin therapy was started or continued. In some patients, sequelae have included amputation of the involved area and/or death. Treatment with COUMADIN may be considered after the platelet count has normalized.
COUMADIN can cause fetal harm when administered to a pregnant woman. While COUMADIN is contraindicated during pregnancy, the potential benefits of using COUMADIN may outweigh the risks for pregnant women with mechanical heart valves at high risk of thromboembolism. In those individual situations, the decision to initiate or continue COUMADIN should be reviewed with the patient, taking into consideration the specific risks and benefits pertaining to the individual patient’s medical situation, as well as the most current medical guidelines. COUMADIN exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1)].
COUMADIN exposure during pregnancy can cause pregnancy loss, birth defects, or fetal death. Discuss pregnancy planning with females of reproductive potential who are on COUMADIN therapy [see Contraindications (4) and Use in Specific Populations (8.8)].
In the following clinical settings, the risks of COUMADIN therapy may be increased:
The following factors may be responsible for increased INR response: diarrhea, hepatic disorders, poor nutritional state, steatorrhea, or vitamin K deficiency.
The following factors may be responsible for decreased INR response: increased vitamin K intake or hereditary warfarin resistance.
The following serious adverse reactions to COUMADIN are discussed in greater detail in other sections of the labeling:
Other adverse reactions to COUMADIN include:
Drugs may interact with COUMADIN through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with COUMADIN are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and alteration of the physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with COUMADIN are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.
More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [see Boxed Warning].
Consult the labeling of all concurrently used drugs to obtain further information about interactions with COUMADIN or adverse reactions pertaining to bleeding.
CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The more potent warfarin S-enantiomer is metabolized by CYP2C9 while the R-enantiomer is metabolized by CYP1A2 and 3A4.
Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table 2; however, this list should not be considered all-inclusive. Consult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential. The CYP450 inhibition and induction potential should be considered when starting, stopping, or changing dose of concomitant mediations. Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer.
Enzyme | Inhibitors | Inducers |
---|---|---|
CYP2C9 | amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, sulfinpyrazone, tigecycline, voriconazole, zafirlukast | aprepitant, bosentan, carbamazepine, phenobarbital, rifampin |
CYP1A2 | acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton | montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking |
CYP3A4 | alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenavir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton | armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, nafcillin, phenytoin, pioglitazone, prednisone, rifampin, rufinamide |
Examples of drugs known to increase the risk of bleeding are presented in Table 3. Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin.
Drug Class | Specific Drugs |
---|---|
Anticoagulants | argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin |
Antiplatelet Agents | aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine |
Nonsteroidal Anti-Inflammatory Agents | celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac |
Serotonin Reuptake Inhibitors | citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone |
There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin.
Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin.
Exercise caution when botanical (herbal) products are taken concomitantly with COUMADIN. Few adequate, well-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and COUMADIN exist. Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation.
Some botanicals may cause bleeding events when taken alone (e.g., garlic and Ginkgo biloba) and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant effects of COUMADIN. Conversely, some botanicals may decrease the effects of COUMADIN (e.g., co-enzyme Q10, St. John’s wort, ginseng). Some botanicals and foods can interact with COUMADIN through CYP450 interactions (e.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. John’s wort).
Monitor the patient’s response with additional INR determinations when initiating or discontinuing any botanicals.
Bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries, unexplained fall in hemoglobin) is a manifestation of excessive anticoagulation.
The treatment of excessive anticoagulation is based on the level of the INR, the presence or absence of bleeding, and clinical circumstances. Reversal of COUMADIN anticoagulation may be obtained by discontinuing COUMADIN therapy and, if necessary, by administration of oral or parenteral vitamin K1.
The use of vitamin K1 reduces response to subsequent COUMADIN therapy and patients may return to a pretreatment thrombotic status following the rapid reversal of a prolonged INR. Resumption of COUMADIN administration reverses the effect of vitamin K, and a therapeutic INR can again be obtained by careful dosage adjustment. If rapid re-anticoagulation is indicated, heparin may be preferable for initial therapy.
Prothrombin complex concentrate (PCC), fresh frozen plasma, or activated Factor VII treatment may be considered if the requirement to reverse the effects of COUMADIN is urgent. A risk of hepatitis and other viral diseases is associated with the use of blood products; PCC and activated Factor VII are also associated with an increased risk of thrombosis. Therefore, these preparations should be used only in exceptional or life-threatening bleeding episodes secondary to COUMADIN overdosage.
COUMADIN (warfarin sodium) is an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Crystalline warfarin sodium is an isopropanol clathrate. Its empirical formula is C19H15NaO4, and its structural formula is represented by the following:
Crystalline warfarin sodium occurs as a white, odorless, crystalline powder that is discolored by light. It is very soluble in water, freely soluble in alcohol, and very slightly soluble in chloroform and ether.
COUMADIN tablets for oral use also contain:
All strengths: | Lactose, starch, and magnesium stearate | |
1 mg: | D&C Red No. 6 Barium Lake | |
2 mg: | FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake |
|
2-1/2 mg: | D&C Yellow No. 10 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake |
|
3 mg: | FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, and FD&C Red No. 40 Aluminum Lake |
|
4 mg: | FD&C Blue No. 1 Aluminum Lake | |
5 mg: | FD&C Yellow No. 6 Aluminum Lake | |
6 mg: | FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake |
|
7-1/2 mg: | D&C Yellow No. 10 Aluminum Lake and FD&C Yellow No. 6 Aluminum Lake |
|
10 mg: | Dye-free |
COUMADIN for injection for intravenous use is supplied as a sterile, lyophilized powder, which, after reconstitution with 2.7 mL Sterile Water for Injection, contains:
Warfarin sodium | 2 mg per mL | |
Sodium phosphate, dibasic, heptahydrate | 4.98 mg per mL | |
Sodium phosphate, monobasic, monohydrate | 0.194 mg per mL | |
Sodium chloride | 0.1 mg per mL | |
Mannitol | 38.0 mg per mL | |
Sodium hydroxide, as needed for pH adjustment to 8.1 to 8.3 |
In five prospective, randomized, controlled clinical trials involving 3711 patients with non-rheumatic AF, warfarin significantly reduced the risk of systemic thromboembolism including stroke (see Table 4). The risk reduction ranged from 60% to 86% in all except one trial (CAFA: 45%), which was stopped early due to published positive results from two of these trials. The incidence of major bleeding in these trials ranged from 0.6% to 2.7% (see Table 4).
N | Thromboembolism | % Major Bleeding | ||||||
---|---|---|---|---|---|---|---|---|
Study | Warfarin- Treated Patients | Control Patients | PT Ratio | INR | % Risk Reduction | p-value | Warfarin- Treated Patients | Control Patients |
*All study results of warfarin vs. control are based on intention-to-treat analysis and include ischemic stroke and systemic thromboembolism, excluding hemorrhagic stroke and transient ischemic attacks. | ||||||||
AFASAK | 335 | 336 | 1.5-2.0 | 2.8-4.2 | 60 | 0.027 | 0.6 | 0.0 |
SPAF | 210 | 211 | 1.3-1.8 | 2.0-4.5 | 67 | 0.01 | 1.9 | 1.9 |
BAATAF | 212 | 208 | 1.2-1.5 | 1.5-2.7 | 86 | <0.05 | 0.9 | 0.5 |
CAFA | 187 | 191 | 1.3-1.6 | 2.0-3.0 | 45 | 0.25 | 2.7 | 0.5 |
SPINAF | 260 | 265 | 1.2-1.5 | 1.4-2.8 | 79 | 0.001 | 2.3 | 1.5 |
Trials in patients with both AF and mitral stenosis suggest a benefit from anticoagulation with COUMADIN [see Dosage and Administration (2.2)].
In a prospective, randomized, open-label, positive-controlled study in 254 patients with mechanical prosthetic heart valves, the thromboembolic-free interval was found to be significantly greater in patients treated with warfarin alone compared with dipyridamole/aspirin-treated patients (p<0.005) and pentoxifylline/aspirin-treated patients (p<0.05). The results of this study are presented in Table 5.
Patients Treated With | ||||||||
---|---|---|---|---|---|---|---|---|
Warfarin | Dipyridamole/Aspirin | Pentoxifylline/Aspirin | ||||||
Event | ||||||||
py=patient years | ||||||||
Thromboembolism | 2.2/100 py | 8.6/100 py | 7.9/100 py | |||||
Major Bleeding | 2.5/100 py | 0.0/100 py | 0.9/100 py |
In a prospective, open-label, clinical study comparing moderate (INR 2.65) vs. high intensity (INR 9.0) warfarin therapies in 258 patients with mechanical prosthetic heart valves, thromboembolism occurred with similar frequency in the two groups (4.0 and 3.7 events per 100 patient years, respectively). Major bleeding was more common in the high intensity group. The results of this study are presented in Table 6.
Event | Moderate Warfarin Therapy INR 2.65 | High Intensity Warfarin Therapy INR 9.0 |
||||||
---|---|---|---|---|---|---|---|---|
py=patient years | ||||||||
Thromboembolism | 4.0/100 py | 3.7/100 py | ||||||
Major Bleeding | 0.95/100 py | 2.1/100 py |
In a randomized trial in 210 patients comparing two intensities of warfarin therapy (INR 2.0-2.25 vs. INR 2.5-4.0) for a three-month period following tissue heart valve replacement, thromboembolism occurred with similar frequency in the two groups (major embolic events 2.0% vs. 1.9%, respectively, and minor embolic events 10.8% vs. 10.2%, respectively). Major hemorrhages occurred in 4.6% of patients in the higher intensity INR group compared to zero in the lower intensity INR group.
WARIS (The Warfarin Re-Infarction Study) was a double-blind, randomized study of 1214 patients 2 to 4 weeks post-infarction treated with warfarin to a target INR of 2.8 to 4.8. The primary endpoint was a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of the patients was 37 months. The results for each endpoint separately, including an analysis of vascular death, are provided in Table 7.
Event | Warfarin (N=607) | Placebo (N=607) | RR (95% CI) | % Risk Reduction (p-value) |
---|---|---|---|---|
RR=Relative risk; Risk reduction=(1 - RR); CI=Confidence interval; MI=Myocardial infarction; py=patient years | ||||
Total Patient Years of Follow-up | 2018 | 1944 | ||
Total Mortality | 94 (4.7/100 py) | 123 (6.3/100 py) | 0.76 (0.60, 0.97) | 24 (p=0.030) |
Vascular Death | 82 (4.1/100 py) | 105 (5.4/100 py) | 0.78 (0.60, 1.02) | 22 (p=0.068) |
Recurrent MI | 82 (4.1/100 py) | 124 (6.4/100 py) | 0.66 (0.51, 0.85) | 34 (p=0.001) |
Cerebrovascular Event | 20 (1.0/100 py) | 44 (2.3/100 py) | 0.46 (0.28, 0.75) | 54 (p=0.002) |
WARIS II (The Warfarin, Aspirin, Re-Infarction Study) was an open-label, randomized study of 3630 patients hospitalized for acute myocardial infarction treated with warfarin to a target INR 2.8 to 4.2, aspirin 160 mg per day, or warfarin to a target INR 2.0 to 2.5 plus aspirin 75 mg per day prior to hospital discharge. The primary endpoint was a composite of death, nonfatal reinfarction, or thromboembolic stroke. The mean duration of observation was approximately 4 years. The results for WARIS II are provided in Table 8.
Event | Aspirin (N=1206) | Warfarin (N=1216) | Aspirin plus Warfarin (N=1208) | Rate Ratio (95% CI) | p-value |
---|---|---|---|---|---|
a Major bleeding episodes were defined as nonfatal cerebral hemorrhage or bleeding necessitating surgical intervention or blood transfusion. | |||||
b The rate ratio is for aspirin plus warfarin as compared with aspirin. | |||||
c The rate ratio is for warfarin as compared with aspirin. | |||||
d Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood transfusion. | |||||
e Includes death, nonfatal reinfarction, and thromboembolic cerebral stroke. | |||||
CI=confidence interval | |||||
ND=not determined | |||||
No. of Events | |||||
Major Bleedinga | 8 | 33 | 28 | 3.35b (ND) 4.00c (ND) | ND ND |
Minor Bleedingd | 39 | 103 | 133 | 3.21b (ND) 2.55c (ND) | ND ND |
Composite Endpointse | 241 | 203 | 181 | 0.81 (0.69-0.95)b
0.71 (0.60-0.83)c | 0.03 0.001 |
Reinfarction | 117 | 90 | 69 | 0.56 (0.41-0.78)b
0.74 (0.55-0.98)c | <0.001 0.03 |
Thromboembolic Stroke | 32 | 17 | 17 | 0.52 (0.28-0.98)b
0.52 (0.28-0.97)c | 0.03 0.03 |
Death | 92 | 96 | 95 | 0.82 |
There were approximately four times as many major bleeding episodes in the two groups receiving warfarin than in the group receiving aspirin alone. Major bleeding episodes were not more frequent among patients receiving aspirin plus warfarin than among those receiving warfarin alone, but the incidence of minor bleeding episodes was higher in the combined therapy group.
See FDA-approved patient labeling (Medication Guide).
Advise patients to:
Distributed by:
Bristol-Myers Squibb Company
Princeton, New Jersey 08543 USA
COUMADIN® is a trademark of Bristol-Myers Squibb Pharma Company.
Copyright © Bristol-Myers Squibb Company 2011
Printed in USA
1274054A0 / 1274029A0 / 1274055A0 / 1274053A0
Rev October 2011
MEDICATION GUIDE
COUMADIN® (COU-ma-din)
(warfarin sodium)
Read this Medication Guide before you start taking COUMADIN (warfarin sodium) and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about COUMADIN when you start taking it and at regular checkups.
What is the most important information I should know about COUMADIN?
COUMADIN can cause bleeding which can be serious and sometimes lead to death. This is because COUMADIN is a blood thinner medicine that lowers the chance of blood clots forming in your body.
Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above.
Many other medicines can interact with COUMADIN and affect the dose you need or increase COUMADIN side effects. Do not change or stop any of your medicines or start any new medicines before you talk to your healthcare provider.
Do not take other medicines that contain warfarin sodium while taking COUMADIN.
See "What are the possible side effects of COUMADIN?" for more information about side effects.
What is COUMADIN?
COUMADIN is prescription medicine used to treat blood clots and to lower the chance of blood clots forming in your body. Blood clots can cause a stroke, heart attack, or other serious conditions if they form in the legs or lungs.
It is not known if COUMADIN is safe and effective in children.
Who should not take COUMADIN?
Do not take COUMADIN if:
What should I tell my healthcare provider before taking COUMADIN?
Before you take COUMADIN, tell your healthcare provider if you:
Tell all of your healthcare providers and dentists that you are taking COUMADIN. They should talk to the healthcare provider who prescribed COUMADIN for you before you have any surgery or dental procedure. Your COUMADIN may need to be stopped for a short time or you may need your dose adjusted.
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way COUMADIN works. Certain medicines may increase your risk of bleeding. See "What is the most important information I should know about COUMADIN?"
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I take COUMADIN?
What should I avoid while taking COUMADIN?
What are the possible side effects of COUMADIN?
COUMADIN may cause serious side effects including:
Tell your healthcare provider if you have any side effect that bothers you or does not go away.
These are not all of the side effects of COUMADIN. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store COUMADIN?
Keep COUMADIN and all medicines out of the reach of children.
General Information about COUMADIN.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use COUMADIN for a condition for which it was not prescribed. Do not give COUMADIN to other people, even if they have the same symptoms that you have. It may harm them.
This Medication Guide summarizes the most important information about COUMADIN. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about COUMADIN that is written for healthcare professionals.
If you would like more information, go to www.coumadin.com or call 1-800-321-1335.
What are the ingredients in COUMADIN?
Active ingredient: Warfarin Sodium
Inactive ingredients: Lactose, starch, and magnesium stearate. The following tablets contain:
1 mg: | D&C Red No. 6 Barium Lake | |
2 mg: | FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake |
|
2-1/2 mg: | D&C Yellow No. 10 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake |
|
3 mg: | FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, and FD&C Red No. 40 Aluminum Lake |
|
4 mg: | FD&C Blue No. 1 Aluminum Lake | |
5 mg: | FD&C Yellow No. 6 Aluminum Lake | |
6 mg: | FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake |
|
7-1/2 mg: | D&C Yellow No. 10 Aluminum Lake and FD&C Yellow No. 6 Aluminum Lake |
This Medication Guide has been approved by the U.S. Food and Drug Administration.
COUMADIN is distributed by:
Bristol-Myers Squibb Company
Princeton, New Jersey 08543 USA
COUMADIN® is a registered trademark of Bristol-Myers Squibb Pharma Company.
**The brands listed (other than COUMADIN®) are registered trademarks of their respective owners and are not trademarks of Bristol-Myers Squibb Company.
1258498A3 / 1215385A4 / 1205734A4 / 1205736A4
Rev October 2011
COUMADIN
warfarin sodium tablet |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
Labeler - Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC (831276758) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC | 831276758 | repack(49999-411) |